SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the second quarter and six months ended June 30, 2008. Revenues for the second quarter were $11.5 million, compared to $36.1 million for the same period in 2007. Net loss for the second quarter was $12.4 million, compared to net income of $13.5 million for the same period in 2007. Revenues and net income for the second quarter of 2007 were positively impacted by recognition of revenue associated with up-front and milestone payments from XenoPort’s collaborations with GlaxoSmithKline, or GSK, and Astellas Pharma Inc. At June 30, 2008, XenoPort had cash, cash equivalents and short-term investments of $150.4 million.
